VanEck Pharmaceutical ETF (NASDAQ:PPH) Hits New 1-Year High at $93.50

VanEck Pharmaceutical ETF (NASDAQ:PPH) shares hit a new 52-week high on Friday . The company traded as high as $93.50 and last traded at $93.50, with a volume of 6127 shares changing hands. The stock had previously closed at $92.82.

VanEck Pharmaceutical ETF Stock Performance

The business’s fifty day moving average is $90.87 and its two-hundred day moving average is $88.35. The company has a market cap of $631.81 million, a P/E ratio of 21.04 and a beta of 0.72.

VanEck Pharmaceutical ETF Cuts Dividend

The business also recently disclosed a dividend, which was paid on Friday, July 5th. Investors of record on Monday, July 1st were issued a dividend of $0.3558 per share. The ex-dividend date was Monday, July 1st.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. CWM LLC purchased a new position in VanEck Pharmaceutical ETF during the 2nd quarter valued at about $55,000. Cetera Advisors LLC purchased a new position in shares of VanEck Pharmaceutical ETF in the 1st quarter worth approximately $606,000. Cetera Investment Advisers grew its position in shares of VanEck Pharmaceutical ETF by 316.1% in the 1st quarter. Cetera Investment Advisers now owns 26,211 shares of the company’s stock worth $2,377,000 after buying an additional 19,912 shares during the last quarter. Comerica Bank grew its position in shares of VanEck Pharmaceutical ETF by 39.4% in the 1st quarter. Comerica Bank now owns 1,337 shares of the company’s stock worth $121,000 after buying an additional 378 shares during the last quarter. Finally, Beck Capital Management LLC grew its position in shares of VanEck Pharmaceutical ETF by 4.5% in the 1st quarter. Beck Capital Management LLC now owns 20,957 shares of the company’s stock worth $1,901,000 after buying an additional 897 shares during the last quarter.

About VanEck Pharmaceutical ETF

The VanEck Pharmaceutical ETF (PPH) is an exchange-traded fund that is based on the MVIS US Listed Pharmaceutical 25 index, a market-cap-weighted index of 25 of the largest global pharmaceutical firms. PPH was launched on Feb 1, 2000 and is managed by VanEck.